GTx Inc (GTXI)

0.78
0.03 4.40
NASDAQ : Health Care
Prev Close 0.75
Open 0.75
Day Low/High 0.74 / 0.78
52 Wk Low/High 0.29 / 1.30
Volume 19.08K
Avg Volume 273.10K
Exchange NASDAQ
Shares Outstanding 141.92M
Market Cap 105.02M
EPS -0.10
P/E Ratio 3.72
Div & Yield N.A. (N.A)

Latest News

GTx Appoints Dr. Garry Neil To Board Of Directors

GTx Appoints Dr. Garry Neil To Board Of Directors

GTx, Inc. (Nasdaq: GTXI) today announced that Garry A.

GTx Provides Corporate Update And Reports Second Quarter 2016 Financial Results

GTx Provides Corporate Update And Reports Second Quarter 2016 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter ended June 30, 2016 and highlighted upcoming milestones.

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny

If the messy, confused clinical data disclosed Saturday by XBiotech are any indication, an approval in Europe for its colon cancer drug is far from a sure thing.

GTx Announces Webcast Of Corporate Presentation At Jefferies 2016 Global Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At Jefferies 2016 Global Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 9, 2016, at the Jefferies 2016 Global Healthcare Conference in New York City.

GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2016

GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2016

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on May 24, 2016, at the UBS Global Healthcare Conference in New York City.

GTx Provides Corporate Update And Reports First Quarter 2016 Financial Results

GTx Provides Corporate Update And Reports First Quarter 2016 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2016, and highlighted recent accomplishments and upcoming milestones.

GTx Announces Presentation Of Preclinical Data Demonstrating The Ability Of SARDs To Degrade And Inhibit The Androgen Receptor At The American Urological Association Annual Meeting

GTx Announces Presentation Of Preclinical Data Demonstrating The Ability Of SARDs To Degrade And Inhibit The Androgen Receptor At The American Urological Association Annual Meeting

GTx, Inc. (Nasdaq: GTXI) today announced the first public presentation of preclinical data from the Company's selective androgen receptor degrader (SARD) program.

GTx, Inc. To Report First Quarter 2016 Financial Results On May 10, 2016

GTx, Inc. To Report First Quarter 2016 Financial Results On May 10, 2016

GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2016 financial results press release will be Tuesday, May 10, 2016, prior to the opening of the U.

GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2015 Financial Results

GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2015 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the fourth quarter and year ended December 31, 2015, and highlighted recent accomplishments and upcoming milestones.

GTx Announces Presentation Of Preclinical Data Demonstrating The Effect Of GTx SARMs On Pelvic Floor Muscle Loss At The Society Of Urodynamics, Female Pelvic Medicine And Urogenital Reconstruction (SUFU) Meeting

GTx Announces Presentation Of Preclinical Data Demonstrating The Effect Of GTx SARMs On Pelvic Floor Muscle Loss At The Society Of Urodynamics, Female Pelvic Medicine And Urogenital Reconstruction (SUFU) Meeting

GTx, Inc. (Nasdaq: GTXI) today announced preclinical data demonstrating that two of the Company's selective androgen receptor modulators (SARMs), GTx-024 (enobosarm) and GTx-027, are able to increase pelvic floor muscle...

GTx, Inc. To Host Fourth Quarter And Full Year 2015 Financial Results Conference Call And Webcast

GTx, Inc. To Host Fourth Quarter And Full Year 2015 Financial Results Conference Call And Webcast

GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full year 2015 financial results on Thursday, March 3, 2016...

GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence

GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced the initiation of its Phase 2 clinical trial to treat postmenopausal women with stress urinary incontinence (SUI).

GTx Provides Corporate Update And Reports Third Quarter 2015 Financial Results

GTx Provides Corporate Update And Reports Third Quarter 2015 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and nine months ended September 30, 2015, and highlighted recent accomplishments and developments.

GTx, Inc. To Host Third Quarter 2015 Financial Results Conference Call And Webcast

GTx, Inc. To Host Third Quarter 2015 Financial Results Conference Call And Webcast

GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2015 financial results on Thursday, October 29, 2015 at 9:00 a.

GTx Receives FDA Clearance To Initiate Clinical Trial In Stress Urinary Incontinence

GTx Receives FDA Clearance To Initiate Clinical Trial In Stress Urinary Incontinence

GTx, Inc. (Nasdaq:GTXI) today announced that the U.

GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer

GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer

GTx, Inc. (Nasdaq: GTXI) today announced the enrollment of the first patient into its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, androgen receptor positive (AR+), triple negative breast...

GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer

GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer

GTx, Inc. (Nasdaq: GTXI) today announced the enrollment of the first patient into its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+), androgen receptor positive...

GTx Provides Corporate Update And Reports Second Quarter 2015 Financial Results

GTx Provides Corporate Update And Reports Second Quarter 2015 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and six months ended June 30, 2015, and highlighted recent accomplishments and developments.

GTx, Inc. To Host Second Quarter 2015 Financial Results Conference Call And Webcast

GTx, Inc. To Host Second Quarter 2015 Financial Results Conference Call And Webcast

GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's second quarter 2015 financial results on Thursday, August 6, 2015 at 9:00 a.

GTx Appoints Diane Young, M.D. As Vice President, Chief Medical Officer

GTx Appoints Diane Young, M.D. As Vice President, Chief Medical Officer

GTx, Inc. (NASDAQ: GTXI) today announced the appointment of Diane C.

GTx Regains Compliance With NASDAQ Bid Price Requirement

GTx Regains Compliance With NASDAQ Bid Price Requirement

GTx, Inc. (Nasdaq: GTXI) today announced that it has received written communication from the NASDAQ Listing Qualifications Panel that the Company has regained compliance with the minimum bid price requirement under the...

GTx Announces Webcast Of Corporate Presentation At Jefferies 2015 Global Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At Jefferies 2015 Global Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that Dr.

GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2015

GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2015

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on May 19, 2015, at the UBS Global Healthcare Conference in New York City.

GTx Provides Corporate Update And Reports First Quarter 2015 Financial Results

GTx Provides Corporate Update And Reports First Quarter 2015 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2015, and highlighted recent accomplishments and upcoming milestones.

3 Stocks Under $10 to Trade for Big Breakouts

3 Stocks Under $10 to Trade for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades.

GTx And The University Of Tennessee Research Foundation Enter Into Exclusive License Agreement To Develop UTRF's SARD Drug Technology

GTx And The University Of Tennessee Research Foundation Enter Into Exclusive License Agreement To Develop UTRF's SARD Drug Technology

GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor...

GTx Provides Corporate Update Regarding NASDAQ Stock Listing

GTx Provides Corporate Update Regarding NASDAQ Stock Listing

GTx, Inc. (Nasdaq: GTXI) today provided an update regarding the initiatives being taken to address the Company's continued listing on The NASDAQ Capital Market.

GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2014 Financial Results

GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2014 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the fourth quarter and year ended December 31, 2014, and highlighted recent accomplishments and upcoming milestones.